Company Leadership Change - Christopher Cherry will assume the role of Interim Chief Financial Officer, replacing David Worner, effective December 8, 2025 [1] - The company expresses gratitude to Mr. Worner for his contributions and wishes him well in future endeavors [1] Stock Options and Restricted Share Units - The company has granted a total of 579,028 stock options, exercisable at $0.84 per share, valid for a term of three to five years [2] - Additionally, 931,112 restricted share units have been issued, valid for a term between two to five years, to executive officers, directors, and consultants [2] - These stock options and restricted share units are part of the company's share compensation plans and are subject to vesting conditions [2] Company Overview - Rocket Doctor AI Inc. provides AI-powered healthcare solutions aimed at improving access to high-quality healthcare throughout the patient journey [3] - The company's technology includes the Global Library of Medicine (GLM), a clinically validated decision support system developed with input from numerous physicians globally [3] Digital Health Platform - Rocket Doctor Inc. operates an AI-powered digital health platform and marketplace, enabling over 300 MDs to provide care for more than 700,000 patient visits [4] - The technology allows doctors to independently launch and manage virtual or hybrid in-person practices, enhancing efficiency and patient access [4] Commitment to Underserved Communities - The company aims to reduce administrative burdens and improve physician-patient interactions, particularly in underserved, rural, and remote communities in Canada [5] - It also supports patients on Medicaid and Medicare in the United States, focusing on making healthcare more scalable, equitable, and patient-centered [5]

Rocket Doctor and Toronto Metropolitan University (TMU) have formed a strategic partnership to leverage the independent physicians on the Rocket Doctor platform to expand clinical education opportunities across TMU’s Medical School.Both organizations will collaborate on joint communications and create streamlined pathways for physicians on Rocket Doctor to engage with TMU and apply for clinical faculty roles.Rocket Doctor will promote and facilitate clinical faculty appointments, verify physician status, su ...

Core Points - CIMG Inc. has been awarded the "Most Investable Company Award" at the 10th Zhitong Finance Capital Market Annual Conference held in Shenzhen, China on December 3, 2025 [1] - The award recognizes outstanding performance among listed companies in the Hong Kong and US stock markets, highlighting exceptional business models and operational performance [2][3] Company Overview - CIMG Inc. specializes in digital health and sales development, utilizing technology and marketing to enhance sales growth and commercial value for its business partners [1] - The company operates within the cryptocurrency and digital wellness industries, leveraging AI and cryptocurrencies to drive industry growth and maximize user acquisition [5] - CIMG's portfolio includes brands such as Kangduoyuan, Maca-Noni, Qianmao, Huomao, and Coco-mango [5] Industry Recognition - The Zhitong Finance Capital Market Annual Conference has become a benchmark event in the industry since its inception in 2016, earning acclaim from global investors [2] - The "Most Investable Company Award" specifically honors companies that consistently deliver value to investors while contributing positively to society through superior products or services [3]

Peer-reviewed JMIR Cardio study demonstrates real-world clinical impact of data-driven digital nudges on hypertension outcomes Data-driven engagement translates to lower health risks and downstream cost savings for Dario clients Results highlight Dario's ability to deliver lasting impact and further cement the Company's position as a proven leader in evidence-based digital care NEW YORK, Dec. 4, 2025 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) (the "Company", "DarioHealth" or "Dario"), a leader in glob ...

Core Insights - Braidwell initiated a new stake in Hinge Health, acquiring 910,476 shares valued at approximately $44.7 million during the third quarter [1][2][3] - Hinge Health's stock price increased by 43% since its IPO, outperforming the S&P 500 index [3] Company Overview - Hinge Health specializes in digital solutions for musculoskeletal health, utilizing a scalable software platform to address chronic pain and rehabilitation needs [6][9] - The company operates a software-as-a-service (SaaS) model, providing subscription-based digital health solutions to large employers, health insurers, and healthcare providers [9][10] Financial Performance - Hinge Health reported a 53% year-over-year revenue increase in the third quarter, reaching $154.2 million [10] - The company's GAAP gross margin expanded to 82%, and free cash flow reached a record $81.3 million [10] - Hinge Health's updated guidance projects full-year revenue growth of 47% and non-GAAP operating income between $106 million and $108 million [12] Market Position - Hinge Health's new position accounts for 1.8% of Braidwell's $2.5 billion in reportable U.S. equity assets under management [3][11] - The company has over 1.5 million lifetime members and a 25% increase in clients, totaling 2,560 [10]

 Vancouver, BC – TheNewswire - December 2, 2025 – XR Immersive Technologies Inc. (CSE: VRAI, OTC: FNTTF, FSE: 79W0) (“XR” or the “Company”) is providing a corporate update following the appointment of Shafin Diamond Tejani as Special Advisor, originally announced on October 9, 2025.Since the appointment, the Company has focused on three core priorities: (1) completing all outstanding financial filings, (2) advancing commercialization of its health-related digital twin technology, and (3) progressing through ...

Core Insights - Mainz Biomed has partnered with DoctorBox to integrate its ColoAlert® test into DoctorBox's digital health platform, enhancing access to colorectal cancer screening at home [1][2][3] - Colorectal cancer is a significant health issue in Germany, with approximately 60,000 new cases diagnosed annually, underscoring the need for effective early detection solutions [2] - The collaboration aims to lower barriers to screening and promote innovative, personalized preventive healthcare solutions [3][4] Company Overview - Mainz Biomed specializes in molecular genetic diagnostics for early cancer detection, with ColoAlert® being its flagship product for colorectal cancer [7] - The company is currently conducting the eAArly DETECT 2 clinical study in preparation for a pivotal FDA study for US regulatory approval [7] - Mainz Biomed's product portfolio also includes PancAlert, an early-stage pancreatic cancer screening test [7] Industry Context - DoctorBox is a leading digital health solution in Europe, with over one million registered users and more than ten million test results transmitted [4][6] - The platform offers a range of preventive healthcare services, including personalized care reminders and at-home tests for various cancers [4][6] - The integration of advanced DNA diagnostics into digital health platforms represents a growing trend in preventive medicine, aiming to make healthcare more accessible [2][3]

Core Insights - DarioHealth Corp. has added 34 new employer clients in the past two weeks, bringing the total to 79 clients year-to-date, exceeding its 2025 target by 98% [1][2][3] - The new clients primarily selected DarioHealth to address cardiometabolic conditions, indicating a market shift towards integrated digital health platforms [2][3] - DarioHealth's platform has demonstrated significant clinical outcomes, including a 1.4% reduction in eHbA1c, a 38% reduction in blood pressure, and an average 10% reduction in Body Mass Index (BMI) among participants [3][4] Company Performance - The revenue from the newly signed clients is expected to begin in Q1 2026, reflecting strong market momentum and demand for DarioHealth's products [1][3] - DarioHealth's platform has shown a 23% lower hospitalization rate and 26% lower all-cause charges compared to traditional care, highlighting its effectiveness [4] Market Position - DarioHealth is positioned as a leader in the digital health market, focusing on chronic conditions management through a user-centric, multi-chronic condition platform [5][6] - The company emphasizes the importance of delivering measurable clinical and financial outcomes, which resonates with self-insured employers [3][4]

Continued organic quarter over quarter revenue growth despite expected summer seasonalityEarnings per share for Q3, 2025: ($0.05) per share.Oversubscribed raise of C$4.23m contributing to significantly improved cash position.Announced signed in-network contracts and credentialing with several major U.S. insurance companies. Extending Rocket Doctor’s U.S. total in-network reach to over 13 million members. Vancouver, British Columbia, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Rocket Doctor AI Inc. (formerly Treatment ...

Core Insights - Victory Square Technologies Inc. reported its financial results for Q3 and nine months ended September 30, 2025, highlighting significant developments across its various platforms, including digital health, biotech, pet wellness, climate tech, and immersive technology [1][4]. Financial Highlights - For Q3 2025, the company achieved adjusted revenue of $12.83 million and GAAP revenue of $10.52 million, with a gross margin of $2.33 million and adjusted EBITDA of $1.26 million [8]. - For the nine months ended September 30, 2025, adjusted revenue reached $26.71 million and GAAP revenue was $20.44 million [8]. Portfolio & Strategic Update - Hydreight Technologies, the flagship digital health subsidiary, continued to drive operational performance, recognized as one of the fastest-growing companies in North America [5][6]. - Hydreight's strategic positioning includes a focus on high-growth health segments such as GLP-1 therapies and hormone optimization, supported by a robust compliance infrastructure [10]. - The company launched a $10 million accelerator to incubate direct-to-consumer health companies scaling on the VSDHOne platform [16]. Digital Health Initiatives - Victory Square supports various digital health platforms, including telehealth and diagnostics, aimed at enhancing metabolic health, dermatology, and preventative health [13]. - The digital health market is experiencing increased adoption, with a projected U.S. healthcare spending reaching $7.2 trillion by 2031 [17]. Biotech and Pet Health Platforms - Insu Therapeutics is advancing its oral insulin tablet development, targeting first-in-human studies for 2026 [19][23]. - Pawsible Ventures launched a $10 million fund to accelerate innovation in pet health, aiming to support 15-20 companies over the next three years [19]. Immersive Technology - XR Immersive Tech is expanding into health-related intellectual property, focusing on digital health applications and patient education [20][24]. - Current development areas include digital twin models for chronic-condition tracking and immersive patient engagement tools [21][27]. Additional Notes - Victory Square manages a diversified portfolio of over 20 companies across various sectors, including digital health, AI, and climate tech [26][35]. - The company is actively reviewing monetization opportunities for non-core assets, including a recent Normal Course Issuer Bid allowing the repurchase of up to 5 million common shares [26].